Currency In USD
| Previous Close | 0.81 |
| Open | 0.8 |
| Day High | 0.85 |
| Day Low | 0.8 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.75 |
| Volume | 345,544 |
| Average Volume | 464,030 |
| Market Cap | 12.28M |
| PE | -0.86 |
| EPS | -0.95 |
| Moving Average 50 Days | 1.65 |
| Moving Average 200 Days | 1.88 |
| Change | 0.01 |
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapiesSAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech compan
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
GlobeNewswire Inc.
Feb 11, 2026 1:00 PM GMT
Pre-Fulfillment Prescribing Now Available in All 50 States, Supporting National LaunchDeveloped and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in cl
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
GlobeNewswire Inc.
Dec 10, 2025 1:00 PM GMT
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal se